OncologyOnline.net

Oncology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Pembrolizumab plus chemotherapy in patients with metastatic squamous non-small-cell lung cancer: protocol-specified final analysis of KEYNOTE-407


In the randomized KEYNOTE-407 study, Pembrolizumab ( Keytruda ) plus Carboplatin and Paclitaxel / nab-Paclitaxel ( chemotherapy ) has significantly improved overall survival ( OS ) and progression-free survival ( PFS ) compared with placebo plus chemotherapy in patients with previously untreated metastatic squamous non-small-cell lung cancer ( NSCLC ).

Investigators have reported updated efficacy outcomes from the protocol-specified final analysis and, for the first time, progression on next line of treatment.

Eligible patients were randomized to chemotherapy plus either Pembrolizumab ( n = 278 ) or placebo ( n = 281 ).

After positive results from the second interim analysis, patients still receiving placebo could cross over to Pembrolizumab monotherapy at the time of confirmed progressive disease.

The primary end points were overall survival ( OS ) and progression-free survival ( PFS ).
PFS-2 ( time from randomization to progression on next-line treatment / death, whichever occurred first ) was an exploratory end point.

After median ( range ) follow-up of 14.3 ( 0.1–31.3 ) months, Pembrolizumab plus chemotherapy continued to exhibit a clinically meaningful improvement over placebo plus chemotherapy in overall survival ( median, 17.1 months [ 95% confidence interval ( CI ): 14.4‒19.9 ] versus 11.6 months [ 95% CI: 10.1‒13.7 ]; hazard ratio [ HR ], 0.71 [ 95% CI: 0.58‒0.88 ] ) and progression-free survival ( median, 8.0 months [ 95% CI: 6.3‒8.4 ] versus 5.1 months [ 95% CI: 4.3‒6.0 ]; HR, 0.57 [ 95% CI: 0.47‒0.69 ] ).
PFS-2 was longer for patients randomized to first-line Pembrolizumab plus chemotherapy ( HR, 0.59 [ 95% CI: 0.49‒0.72 ] ).

Grade 3 to 5 adverse events occurred in 74.1% and 69.6% of patients receiving Pembrolizumab plus chemotherapy and placebo plus chemotherapy, respectively.

In conclusion, Pembrolizumab plus chemotherapy continued to exhibit substantially improved overall survival and progression-free survival in patients with metastatic squamous NSCLC.
The PFS-2 outcomes support Pembrolizumab plus chemotherapy as a standard first-line treatment in patients with metastatic squamous non-small-cell lung cancer. ( Xagena )

Paz-Ares L et al, J Thorac Oncol 2020;15: 1657-1669

XagenaMedicine_2020



Indietro